search
Back to results

Exogenous Ketones in People With Type 1 Diabetes

Primary Purpose

Ketosis, Diabetic

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Ketone ester supplement
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Ketosis, Diabetic

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Type 1 diabetes for >1 year
  • Male and female aged 18-45 years old
  • HbA1c <8.5% (69 mmol/mol) based on analysis from the central laboratory unit of Bern University Hospital
  • Using either continuous subcutaneous insulin infusion or multiple daily injections
  • Wearing a continuous glucose monitor (CGM) or flash glucose monitor (fGM)
  • Written informed consent

Exclusion Criteria:

  • Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the results as judged by the investigator
  • Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 agonists
  • Relevant diabetic complications as judged by the investigator
  • Body mass index > 30 kg/m2
  • Uncontrolled hypertension (>180/100 mmHg)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Low-dose KE

    High-dose KE

    Arm Description

    141 mg/kg bodyweight of ketone esters

    282 mg/kg bodyweight of ketone esters

    Outcomes

    Primary Outcome Measures

    Change in venous blood pH
    Change in blood pH over a 3 hour period from baseline following ingestion of a ketone ester drink

    Secondary Outcome Measures

    Blood total ketone level /beta hydroxy butyrate level
    Blood glucose concentration
    Substrate oxidation rates determined using indirect calorimetry, via RER (respiratory exchange ratio)
    Gastro-intestinal distress symptoms via a questionnaire

    Full Information

    First Posted
    July 22, 2020
    Last Updated
    August 30, 2023
    Sponsor
    Insel Gruppe AG, University Hospital Bern
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04487678
    Brief Title
    Exogenous Ketones in People With Type 1 Diabetes
    Official Title
    A Single-centre, Randomised, Single-blinded Crossover Study Evaluating the Metabolic Effects of a Ketone Ester Food Supplement in People With Type 1 Diabetes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Prioritization of other projects
    Study Start Date
    August 2023 (Anticipated)
    Primary Completion Date
    November 2023 (Anticipated)
    Study Completion Date
    December 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Insel Gruppe AG, University Hospital Bern

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The aim of this pilot study is to investigate the metabolic effects of exogenous ketone ester food supplements, by assessing the change in blood acid-base balance, and the level of blood beta-hydroxy-butyrate in people with type 1 diabetes during resting conditions.
    Detailed Description
    The ketone bodies acetoacetate, β-hydroxybutyrate (βHB) and acetone are small lipid-derived molecules that are produced in the liver under certain conditions such as starvation, very low carbohydrate intake and prolonged glycogen-depleting exercise. Ketone bodies serve as an alternative energy substrate for the brain and other metabolically active tissues under periods of low glucose availability, and can modulate carbohydrate and lipid metabolism. Previously, controlled physiological ketosis required a low carbohydrate diet, starvation or administration of acetoacetate (AcAc) salts which were all unpleasant or potentially harmful. The development of ketone esters provides an alternative method to increase βHB levels, and has been shown to be well tolerated in rodents and humans. Two examples are the R,S-1,3-butanediol acetoacetate diester and the (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester. Ingestion of either have been shown to result in short-term (0.5-6 hours) nutritional ketosis (βHB >1mM). Nutritional ketosis can therefore be achieved without the need for the impracticality of ketogenic dieting or fasting. In recent years there has been considerable interest in ketone body food supplements due to their potential for improved exercise performance and therapeutic glucose lowering effects in people with type 2 diabetes. Exogenous ketone supplements may be of particular interest for individuals living with type 1 diabetes by serving as an alternative fuel substrate to reduce the reliance on glucose utilisation and spare endogenous glycogen and reduce the risk of hypoglycaemia in certain situations, such as exercise. Stubbs et al. (2017) found that drinks containing exogenous ketones were a practical and efficacious way to raise blood βHB levels with only a modest change in acid-base balance in healthy individuals without diabetes (after 60 min, blood pH declined from 7.41 to 7.31 following a ketone ester drink). To date, no studies have investigated the metabolic effects of ketone in people with type 1 diabetes.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Ketosis, Diabetic

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Model Description
    Single-centre, randomised, single blinded, crossover study in 6 individuals with type 1 diabetes (see inclusion/exclusion criteria)
    Masking
    Participant
    Masking Description
    There will be two intervention arms that will take place in a randomised, single blinded fashion so that participants are not aware of which dose of ketone esters they receive
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Low-dose KE
    Arm Type
    Experimental
    Arm Description
    141 mg/kg bodyweight of ketone esters
    Arm Title
    High-dose KE
    Arm Type
    Experimental
    Arm Description
    282 mg/kg bodyweight of ketone esters
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Ketone ester supplement
    Other Intervention Name(s)
    H.V.M.N Ketone Ester food supplement
    Intervention Description
    Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
    Primary Outcome Measure Information:
    Title
    Change in venous blood pH
    Description
    Change in blood pH over a 3 hour period from baseline following ingestion of a ketone ester drink
    Time Frame
    Over a 3 hour period from baseline following ingestion of a ketone ester drink in people with type 1 diabetes.
    Secondary Outcome Measure Information:
    Title
    Blood total ketone level /beta hydroxy butyrate level
    Time Frame
    3 hours
    Title
    Blood glucose concentration
    Time Frame
    3 hours
    Title
    Substrate oxidation rates determined using indirect calorimetry, via RER (respiratory exchange ratio)
    Time Frame
    3 hours
    Title
    Gastro-intestinal distress symptoms via a questionnaire
    Time Frame
    3 hours

    10. Eligibility

    Sex
    Male
    Gender Based
    Yes
    Gender Eligibility Description
    Males
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Type 1 diabetes for >1 year Male and female aged 18-45 years old HbA1c <8.5% (69 mmol/mol) based on analysis from the central laboratory unit of Bern University Hospital Using either continuous subcutaneous insulin infusion or multiple daily injections Wearing a continuous glucose monitor (CGM) or flash glucose monitor (fGM) Written informed consent Exclusion Criteria: Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the results as judged by the investigator Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 agonists Relevant diabetic complications as judged by the investigator Body mass index > 30 kg/m2 Uncontrolled hypertension (>180/100 mmHg)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Christoph Stettler, MD
    Organizational Affiliation
    University of Bern
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    2656155
    Citation
    Balasse EO, Fery F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev. 1989 May;5(3):247-70. doi: 10.1002/dmr.5610050304.
    Results Reference
    background
    PubMed Identifier
    22561291
    Citation
    Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, Ho M, Roberts A, Robertson J, Vanitallie TB, Veech RL. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012 Aug;63(3):401-8. doi: 10.1016/j.yrtph.2012.04.008. Epub 2012 May 3.
    Results Reference
    background
    PubMed Identifier
    25379174
    Citation
    Cox PJ, Clarke K. Acute nutritional ketosis: implications for exercise performance and metabolism. Extrem Physiol Med. 2014 Oct 29;3:17. doi: 10.1186/2046-7648-3-17. eCollection 2014.
    Results Reference
    background
    PubMed Identifier
    27475046
    Citation
    Cox PJ, Kirk T, Ashmore T, Willerton K, Evans R, Smith A, Murray AJ, Stubbs B, West J, McLure SW, King MT, Dodd MS, Holloway C, Neubauer S, Drawer S, Veech RL, Griffin JL, Clarke K. Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes. Cell Metab. 2016 Aug 9;24(2):256-68. doi: 10.1016/j.cmet.2016.07.010. Epub 2016 Jul 27.
    Results Reference
    background
    PubMed Identifier
    29473164
    Citation
    Egan B. The glucose-lowering effects of exogenous ketones: is there therapeutic potential? J Physiol. 2018 Apr 15;596(8):1317-1318. doi: 10.1113/JP275938. Epub 2018 Mar 24. No abstract available.
    Results Reference
    background
    PubMed Identifier
    27626197
    Citation
    Egan B, D'Agostino DP. Fueling Performance: Ketones Enter the Mix. Cell Metab. 2016 Sep 13;24(3):373-375. doi: 10.1016/j.cmet.2016.08.021.
    Results Reference
    background
    PubMed Identifier
    27861911
    Citation
    Evans M, Cogan KE, Egan B. Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation. J Physiol. 2017 May 1;595(9):2857-2871. doi: 10.1113/JP273185. Epub 2016 Dec 7.
    Results Reference
    background
    PubMed Identifier
    10702749
    Citation
    Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48. doi: 10.1038/sj.ijo.0801083.
    Results Reference
    background
    PubMed Identifier
    26855664
    Citation
    Kesl SL, Poff AM, Ward NP, Fiorelli TN, Ari C, Van Putten AJ, Sherwood JW, Arnold P, D'Agostino DP. Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Sprague-Dawley rats. Nutr Metab (Lond). 2016 Feb 4;13:9. doi: 10.1186/s12986-016-0069-y. eCollection 2016.
    Results Reference
    background
    PubMed Identifier
    29446830
    Citation
    Myette-Cote E, Neudorf H, Rafiei H, Clarke K, Little JP. Prior ingestion of exogenous ketone monoester attenuates the glycaemic response to an oral glucose tolerance test in healthy young individuals. J Physiol. 2018 Apr 15;596(8):1385-1395. doi: 10.1113/JP275709. Epub 2018 Mar 2. Erratum In: J Physiol. 2019 Nov;597(22):5515. Abstract corrected.
    Results Reference
    background
    PubMed Identifier
    27430501
    Citation
    Pinckaers PJ, Churchward-Venne TA, Bailey D, van Loon LJ. Ketone Bodies and Exercise Performance: The Next Magic Bullet or Merely Hype? Sports Med. 2017 Mar;47(3):383-391. doi: 10.1007/s40279-016-0577-y.
    Results Reference
    background
    PubMed Identifier
    6986618
    Citation
    Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev. 1980 Jan;60(1):143-87. doi: 10.1152/physrev.1980.60.1.143. No abstract available.
    Results Reference
    background
    PubMed Identifier
    29163194
    Citation
    Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, Magor-Elliott S, Hiyama S, Stirling M, Clarke K. On the Metabolism of Exogenous Ketones in Humans. Front Physiol. 2017 Oct 30;8:848. doi: 10.3389/fphys.2017.00848. eCollection 2017.
    Results Reference
    background

    Learn more about this trial

    Exogenous Ketones in People With Type 1 Diabetes

    We'll reach out to this number within 24 hrs